Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.
Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, Beyar-Katz O, Shefer G, Moshiashvili MM, Karni C, Gold R, Kay S, Glait-Santar C, Eshel R, Perry C, Avivi I, Apel A, Benyamini N, Shasha D, Ben-Ami R.
Ram R, et al. Among authors: eshel r.
Transplant Cell Ther. 2021 Sep;27(9):788-794. doi: 10.1016/j.jtct.2021.06.024. Epub 2021 Jun 30.
Transplant Cell Ther. 2021.
PMID: 34214738
Free PMC article.